PURPOSE: In this study, we sought to 1) describe elements of the financial and quality-of-life burden of dysfunctional uterine bleeding (DUB) from the perspective of women who agreed to obtain surgical treatment; 2) explore associations between DUB symptom characteristics and the financial and quality-of-life burden; 3) estimate the annual dollar value of the financial burden; and 4) estimate the most that could be spent on surgery to eliminate DUB symptoms for which medical treatment has been unsuccessful that would result in a $50,000/quality-adjusted life-year incremental cost-effectiveness ratio. METHODS: We collected baseline data on DUB symptoms and aspects of the financial and quality-of-life burden for 237 women agreeing to surgery for DUB in a randomized trial comparing hysterectomy with endometrial ablation. Measures included out-of-pocket pharmaceutical expenditures, excess expenditures on pads or tampons, the value of time missed from paid work and home management activities, and health utility. We used chi2 and t tests to assess the statistical significance of associations between DUB characteristics and the financial and quality-of-life burden. The annual financial burden was estimated. RESULTS:Pelvic pain and cramps were associated with activity limitations and tiredness was associated with a lower health utility. Excess pharmaceutical and pad and tampon costs were $333 per patient per year (95% confidence interval [CI], $263-$403). Excess paid work and home management loss costs were $2,291 per patient per year (95% CI, $1847-$2752). Effective surgical treatment costing $40,000 would be cost-effective compared with unsuccessful medical treatment. CONCLUSION: The financial and quality-of-life effects of DUB represent a substantial burden.
RCT Entities:
PURPOSE: In this study, we sought to 1) describe elements of the financial and quality-of-life burden of dysfunctional uterine bleeding (DUB) from the perspective of women who agreed to obtain surgical treatment; 2) explore associations between DUB symptom characteristics and the financial and quality-of-life burden; 3) estimate the annual dollar value of the financial burden; and 4) estimate the most that could be spent on surgery to eliminate DUB symptoms for which medical treatment has been unsuccessful that would result in a $50,000/quality-adjusted life-year incremental cost-effectiveness ratio. METHODS: We collected baseline data on DUB symptoms and aspects of the financial and quality-of-life burden for 237 women agreeing to surgery for DUB in a randomized trial comparing hysterectomy with endometrial ablation. Measures included out-of-pocket pharmaceutical expenditures, excess expenditures on pads or tampons, the value of time missed from paid work and home management activities, and health utility. We used chi2 and t tests to assess the statistical significance of associations between DUB characteristics and the financial and quality-of-life burden. The annual financial burden was estimated. RESULTS:Pelvic pain and cramps were associated with activity limitations and tiredness was associated with a lower health utility. Excess pharmaceutical and pad and tampon costs were $333 per patient per year (95% confidence interval [CI], $263-$403). Excess paid work and home management loss costs were $2,291 per patient per year (95% CI, $1847-$2752). Effective surgical treatment costing $40,000 would be cost-effective compared with unsuccessful medical treatment. CONCLUSION: The financial and quality-of-life effects of DUB represent a substantial burden.
Authors: Kristen A Matteson; Husam Abed; Thomas L Wheeler; Vivian W Sung; David D Rahn; Joseph I Schaffer; Ethan M Balk Journal: J Minim Invasive Gynecol Date: 2011-11-11 Impact factor: 4.137
Authors: Kristen A Matteson; Britta L Anderson; Stephanie B Pinto; Vrishali Lopes; Jay Schulkin; Melissa A Clark Journal: Am J Obstet Gynecol Date: 2011-05-14 Impact factor: 8.661
Authors: Kristen A Matteson; Christina A Raker; Melissa A Clark; Kevin D Frick Journal: J Womens Health (Larchmt) Date: 2013-09-19 Impact factor: 2.681
Authors: Erica E Marsh; Maureen E Brocks; Marissa S Ghant; Hannah S Recht; Melissa Simon Journal: Int J Gynaecol Obstet Date: 2014-01-02 Impact factor: 3.561